
News|Articles|November 1, 2002
HMG CoA reductase inhibitor-induced muscle toxicity: risks, monitoring, and management (PDF)
Although the commonly used HMG CoA reductase inhibitors (statins) are well tolerated and relatively safe, muscle toxicity and rhabdomyolysis can occur with administration and can be severe. This risk is higher with more bioavailable and lipophilic statins. This article summarizes what is known about the etiology of statin-associated muscle toxicity, the risks for each statin, and the current recommendations for monitoring and management.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
2
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
3
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2025
4
Healthcare’s workforce has a scale problem, but new model is emerging
5


























